{
    "clinical_study": {
        "@rank": "162941", 
        "acronym": "RAPID", 
        "arm_group": [
            {
                "arm_group_label": "Low Frequency Magnetic Stimulation", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this arm will receive 4 days of active low frequency magnetic stimulation (LFMS) treatment, a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes."
            }, 
            {
                "arm_group_label": "Sham (LFMS)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "4 days of sham (not active) low frequency magnetic stimulation (LFMS)."
            }, 
            {
                "arm_group_label": "Crossover Arm", 
                "arm_group_type": "Other", 
                "description": "Patients in this group will receive two days of sham low frequency magnetic stimulation (LFMS) followed by two days of active LFMS."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is looking at the safety and efficacy of low frequency magnetic stimulation\n      (LFMS) for treating patients with treatment resistant depression who are taking an\n      antidepressant that is not working for them."
        }, 
        "brief_title": "Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Treatment Resistant Depression", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, 18-65 years old\n\n          -  Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major\n             Depressive Episode (MDE) of at least eight weeks\n\n          -  A participant has TRD of the current MDE\n\n          -  Good general health\n\n          -  For female participants, status of non-childbearing potential or use of an acceptable\n             form of birth control\n\n          -  Body mass index between 18-40 kg/m2\n\n          -  Concurrent psychotherapy will be allowed if the type and frequency of the therapy has\n             been stable for at least three months prior to screening is expected to remain stable\n             during participation in the study\n\n          -  Concurrent hypnotic therapy will be allowed if the therapy has been stable for at\n             least 4 weeks prior to screening and is expected to remain stable during the\n             subject's participation in the study\n\n        Exclusion Criteria:\n\n          -  A woman of childbearing potential who is not willing to use one of the specified\n             forms of birth control during the study\n\n          -  Pregnant or breastfeeding\n\n          -  A woman with a positive pregnancy test at screening or baseline\n\n          -  Participant has TRD of the current MDE with failure to achieve a satisfactory\n             response) as perceived by the subject to >3 treatment courses of a therapeutic dose\n             of an antidepressant therapy at least six weeks duration\n\n          -  Participant has a current diagnosis of a Substance Use Disorder with the exception of\n             nicotine dependence, at screening or within six months prior to screening\n\n          -  Current diagnosis of Axis I disorders other than Generalized Anxiety Disorder, Social\n             Anxiety Disorder, Panic Disorder, Specific Phobia, Post Traumatic Stress Disorder or\n             Complicated Grief (unless one of these is comorbid and clinically unstable, and/or\n             the focus of the participant's treatment for the past six months or more).\n\n          -  Subject has a history of schizophrenia or schizoaffective disorders, any history of\n             psychotic symptoms or is on antipsychotic medication for the treatment of psychotic\n             symptoms\n\n          -  Subject has a history of eating disorders within five years of screening\n\n          -  Subject has any Axis I or Axis II Disorder, which at screening is clinically\n             predominant to their MDD or has been predominant at any time within six months prior\n             to screening\n\n          -  The participant is considered at significant risk for suicide during the study\n\n          -  Subject has had electroconvulsive therapy in the current episode of depression\n\n          -  Subject has had Transcranial Magnetic Stimulation or has received treatment with\n             other experimental devices for the treatment in the current episode of depression\n\n          -  Subject has received Vagus Nerve Stimulation at any time\n\n          -  Dementia, delirium, amnestic, or other cognitive disorders\n\n          -  There is a clinically significant abnormality on the screening physical examination\n\n          -  Participation in any clinical trial with an investigational drug or device within the\n             past month or concurrent to study participation\n\n          -  Known history or current episode of:\n\n             --Uncontrolled hypertension, Recent myocardial infarction (within one year) or a\n             history of more than one myocardial infarction, Syncopal event within the past year,\n             Congestive heart failure, Angina pectoris\n\n          -  Chronic lung disease\n\n          -  Lifetime history of surgical procedures involving the brain or meninges encephalitis,\n             meningitis, degenerative central nervous system disorder, epilepsy, mental\n             retardation, any other disease/procedure/accident/intervention associated with\n             significant injury to or malfunction of the central nervous system, history of\n             significant head trauma within the past two years, or is currently receiving\n             anticonvulsant therapy\n\n          -  Lab abnormalities are present\n\n          -  History of hypothyroidism and has been on a stable dosage of thyroid replacement\n             medication, or was surgically treated less than six months prior to screening\n\n          -  Any current or past history of any physical condition which in the investigator's\n             opinion might put the subject at risk or interfere with the interpretation of study\n             results\n\n          -  History of positive screening urine test for drugs of abuse\n\n          -  Patient with any non-removable stimulation device\n\n          -  Patients requiring treatment with excluded concomitant medications\n\n          -  Patients who cannot be in a MRI\n\n          -  Patients who are unable to lie on their back for 20 minutes or more\n\n          -  Patients who are currently using a metal intrauterine device (IUD)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654796", 
            "org_study_id": "2012P001233"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low Frequency Magnetic Stimulation", 
                    "Crossover Arm"
                ], 
                "description": "The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.", 
                "intervention_name": "Low Frequency Magnetic Stimulation (LFMS)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Sham (LFMS)", 
                    "Crossover Arm"
                ], 
                "description": "SHam LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.", 
                "intervention_name": "Sham LFMS", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antidepressive Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Depression", 
            "Treatment Resistant Depression"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35205"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06511"
                    }, 
                    "name": "Yale University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai School of Medecine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "University of Texas Southwestern"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression", 
        "overall_official": [
            {
                "affiliation": "Mount Sinai School of Medecine", 
                "last_name": "Dan Iosifescu, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Yale University", 
                "last_name": "Gerald Sanacora, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Texas", 
                "last_name": "Madhukar Trivedi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Massachusetts General Hospital (Coordinating Center)", 
                "last_name": "Maurizio Fava, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Emory University", 
                "last_name": "Mark Rapaport, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Univsity of Alabama at Birmingham", 
                "last_name": "Richard Shelton, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Massachusetts General Hospital", 
                "last_name": "George I Papakostas, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This instrument is completed with a structured interview guide  by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week.The time frame for this scale is the past 24 hours.", 
            "measure": "Hamilton Rating Scale for Depression - 6 items", 
            "safety_issue": "No", 
            "time_frame": "past 24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654796"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Maurizio Fava, MD", 
            "investigator_title": "Overall Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Mental Health (NIMH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Yale University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Mount Sinai School of Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Texas Southwestern Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Alabama at Birmingham", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Emory University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}